Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

CATECHOLAMINE MEASURES FOR DIAGNOSIS AND TREATMENT OF PATIENTS WITH DEPRESSIVE-DISORDERS JOURNAL OF CLINICAL PSYCHIATRY Schatzberg, A. F., Orsulak, P. J., ROSENBAUM, A. H., KRUGER, E. R., Schildkraut, J. J., Cole, J. O. 1980; 41 (12): 35-39

Abstract

Measurement of the catecholamine's, norepinephrine, epinephrine, metanephrine, normetanephrine, vanilmandelic acid, and 3-methoxy-4-hydroxyphenyl-glycol (MHPG) show certain statistical correlations with three clinical diagnoses. These conditions are as follows: 1) bipolar and schizo-affective depression, 2) unipolar nonendogenous depressions, and 3) schizophrenia related depressions. More specifically MHPG acts to predict which patients will require higher doses of medication, higher plasma levels, and longer treatment periods to respond to treatment.

View details for Web of Science ID A1980KV18700007

View details for PubMedID 7440524